Compare Medtronic PLC (MDT) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Union Pacific Corporation — how do they compare? Medtronic PLC trades at $90.79 (market cap $116.07B), while Union Pacific Corporation trades at $293.38 (market cap $173.99B). The key difference: Union Pacific Corporation is the larger of the two by market cap, and Medtronic PLC pays the higher dividend (3.18%). Which is the better fit depends on your goals.
| MDT | UNP | |
|---|---|---|
Market Cap | $116.07B | $173.99B |
Sector | Health | Industrials |
52-Week High | $105.35 | $307.32 |
52-Week Low | $73.75 | $214.91 |
Enterprise Value | $134.82B | $203.04B |
Dividend Yield | 3.18% | 1.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $89.99, up 0.65% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with consistent earnings beats, 13.2% net income margin, and positive cash flow trends. Recent product innovations including the Hugo robotic surgery platform and AI surgical tools position MDT for growth. Analyst consensus remains strongly positive with 60% buy ratings and $98.75 price target.
MDT presents a compelling investment case with steady revenue growth, dividend aristocrat status, and technological leadership in medical devices. Key risks include increasing debt levels and competitive pressures from Intuitive Surgical. The stock's current valuation at 24.31 P/E appears reasonable given growth prospects, with upside potential to consensus targets if execution continues.
Union Pacific (UNP) trades at $293.85, up 0.55% with neutral technical signals. The company demonstrates strong fundamentals with Q2 2026 EPS beating estimates at $3.41 versus $3.26 expected, marking the second consecutive quarterly beat. Revenue growth of 12% year-over-year and improved operating efficiency support management's raised full-year EPS guidance. The stock maintains robust profitability metrics including 28.85% net margin and 39.7% ROE, though valuation multiples remain elevated with P/E at 23.71.
Outlook remains positive with analyst consensus price target of $334.33 representing 14% upside potential. Key catalysts include service-led growth driving margin expansion and the pending Norfolk Southern merger offering strategic benefits. Risks include high fuel costs, regulatory scrutiny of the merger, and macroeconomic pressures on freight volumes. Institutional ownership trends show continued accumulation by major funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
